The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology

Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) share molecular mechanisms that cause the pathological symptoms they have in common. Here, we review evidence suggesting that hyperactivity of the EGFR/ADAM17 axis plays a role in the development of chronic lung disease in both CF...

Full description

Saved in:
Bibliographic Details
Main Authors: Marta Stolarczyk, Bob J. Scholte
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2018/1067134
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832560441551749120
author Marta Stolarczyk
Bob J. Scholte
author_facet Marta Stolarczyk
Bob J. Scholte
author_sort Marta Stolarczyk
collection DOAJ
description Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) share molecular mechanisms that cause the pathological symptoms they have in common. Here, we review evidence suggesting that hyperactivity of the EGFR/ADAM17 axis plays a role in the development of chronic lung disease in both CF and COPD. The ubiquitous transmembrane protease A disintegrin and metalloprotease 17 (ADAM17) forms a functional unit with the EGF receptor (EGFR), in a feedback loop interaction labeled the ADAM17/EGFR axis. In airway epithelial cells, ADAM17 sheds multiple soluble signaling proteins by proteolysis, including EGFR ligands such as amphiregulin (AREG), and proinflammatory mediators such as the interleukin 6 coreceptor (IL-6R). This activity can be enhanced by injury, toxins, and receptor-mediated external triggers. In addition to intracellular kinases, the extracellular glutathione-dependent redox potential controls ADAM17 shedding. Thus, the epithelial ADAM17/EGFR axis serves as a receptor of incoming luminal stress signals, relaying these to neighboring and underlying cells, which plays an important role in the resolution of lung injury and inflammation. We review evidence that congenital CFTR deficiency in CF and reduced CFTR activity in chronic COPD may cause enhanced ADAM17/EGFR signaling through a defect in glutathione secretion. In future studies, these complex interactions and the options for pharmaceutical interventions will be further investigated.
format Article
id doaj-art-5e3355c75c8f4ce3bd1a035f0b22c5a2
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-5e3355c75c8f4ce3bd1a035f0b22c5a22025-02-03T01:27:34ZengWileyMediators of Inflammation0962-93511466-18612018-01-01201810.1155/2018/10671341067134The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung PathologyMarta Stolarczyk0Bob J. Scholte1Cell Biology, Erasmus MC, Rotterdam, NetherlandsCell Biology, Erasmus MC, Rotterdam, NetherlandsChronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) share molecular mechanisms that cause the pathological symptoms they have in common. Here, we review evidence suggesting that hyperactivity of the EGFR/ADAM17 axis plays a role in the development of chronic lung disease in both CF and COPD. The ubiquitous transmembrane protease A disintegrin and metalloprotease 17 (ADAM17) forms a functional unit with the EGF receptor (EGFR), in a feedback loop interaction labeled the ADAM17/EGFR axis. In airway epithelial cells, ADAM17 sheds multiple soluble signaling proteins by proteolysis, including EGFR ligands such as amphiregulin (AREG), and proinflammatory mediators such as the interleukin 6 coreceptor (IL-6R). This activity can be enhanced by injury, toxins, and receptor-mediated external triggers. In addition to intracellular kinases, the extracellular glutathione-dependent redox potential controls ADAM17 shedding. Thus, the epithelial ADAM17/EGFR axis serves as a receptor of incoming luminal stress signals, relaying these to neighboring and underlying cells, which plays an important role in the resolution of lung injury and inflammation. We review evidence that congenital CFTR deficiency in CF and reduced CFTR activity in chronic COPD may cause enhanced ADAM17/EGFR signaling through a defect in glutathione secretion. In future studies, these complex interactions and the options for pharmaceutical interventions will be further investigated.http://dx.doi.org/10.1155/2018/1067134
spellingShingle Marta Stolarczyk
Bob J. Scholte
The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology
Mediators of Inflammation
title The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology
title_full The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology
title_fullStr The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology
title_full_unstemmed The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology
title_short The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology
title_sort egfr adam17 axis in chronic obstructive pulmonary disease and cystic fibrosis lung pathology
url http://dx.doi.org/10.1155/2018/1067134
work_keys_str_mv AT martastolarczyk theegfradam17axisinchronicobstructivepulmonarydiseaseandcysticfibrosislungpathology
AT bobjscholte theegfradam17axisinchronicobstructivepulmonarydiseaseandcysticfibrosislungpathology
AT martastolarczyk egfradam17axisinchronicobstructivepulmonarydiseaseandcysticfibrosislungpathology
AT bobjscholte egfradam17axisinchronicobstructivepulmonarydiseaseandcysticfibrosislungpathology